Hypoglycemic Accuracy and Improved Low @entity413 Alerts of the Latest Dexcom G4 XXXX Continuous @entity413 Monitoring System.

@entity1 @entity3363 @entity73 @entity4053 @entity413 @entity902 @entity2145
OBJECTIVE: Accuracy of continuous @entity413 monitoring (CGM) devices in @entity4053 has been a widely reported shortcoming of this technology. We report the accuracy in @entity4053 of a new version of the Dexcom (San Diego, CA) G4 @entity902 CGM system (software 505) and present results regarding the optimum setting of CGM hypoglycemic alerts. MATERIALS AND METHODS: CGM values were compared with YSI analyzer (YSI Life Sciences, Yellow Springs, @entity2145 ) measurements every 15   min. We reviewed the accuracy of the CGM system in the hypoglycemic range using standard metrics. We analyzed the time required for the CGM system to detect biochemical @entity4053 (70   mg/dL) compared with the YSI with alert settings at 70   mg/dL and 80   mg/dL. We also analyzed the time between the YSI value crossing 55   mg/dL, defined as the threshold for @entity73 due to @entity4053 , and when the CGM system alerted for @entity4053 . RESULTS: The mean absolute difference for a @entity413 level of less than 70   mg/dL was 6   mg/dL. Ninety-six percent of CGM values were within 20   mg/dL of the YSI values between 40 and 80   mg/dL. When the CGM hypoglycemic alert was set at 80   mg/dL, the device provided an alert for biochemical @entity4053 within 10   min in 95% of instances and at least a 10-min advance warning before the @entity73 threshold in 91% of instances in the study. CONCLUSIONS: Use of an 80   mg/dL threshold setting for hypoglycemic alerts on the G4 @entity902 (software 505) may provide @entity1 with timely warning of @entity4053 before the onset of @entity73 , enabling them to treat themselves for @entity4053 with fast-acting @entity3363 and prevent neuroglycopenia associated with very low @entity413 levels.
